Recursion Pharmaceuticals... (RXRX)
AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Bid | 7.37 |
Market Cap | 2.83B |
Revenue (ttm) | - |
Net Income (ttm) | - |
EPS (ttm) | -1.54 |
PE Ratio (ttm) | -4.79 |
Forward PE | n/a |
Analyst | Buy |
Ask | 7.38 |
Volume | 43,694,593 |
Avg. Volume (20D) | 15,493,866 |
Open | 8.12 |
Previous Close | 7.92 |
Day's Range | 7.34 - 8.28 |
52-Week Range | 5.60 - 15.74 |
Beta | undefined |
About RXRX
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial...
Analyst Forecast
According to 4 analyst ratings, the average rating for RXRX stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 22.03% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
Why Price Moved
News

1 month ago · seekingalpha.com
Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjac...